TL;DR: Financial Overview - Revenue, Profits & Key Metrics

Latest Quarterly: Mar 2025

Income Metrics

Revenue 13.3B
Gross Profit 9.3B 70.01%
Operating Income 4.0B 29.84%
Net Income 1.3B 9.66%
EPS (Diluted) $0.72

Balance Sheet Metrics

Total Assets 136.2B
Total Liabilities 134.7B
Shareholders Equity 1.5B
Debt to Equity 92.14

Cash Flow Metrics

Operating Cash Flow 2.3B
Free Cash Flow 1.4B

Revenue & Profitability Trend

AbbVie Income Statement From 2020 to 2024

Metric20242023202220212020
Revenue i56.3B54.3B58.1B56.2B45.8B
Cost of Goods Sold i16.9B20.4B17.4B17.4B15.4B
Gross Profit i39.4B33.9B40.6B38.8B30.4B
Gross Margin % i70.0%62.4%70.0%69.0%66.4%
Operating Expenses
Research & Development i12.8B8.5B7.2B8.0B7.8B
Selling, General & Administrative i14.8B12.9B15.3B12.3B11.3B
Other Operating Expenses i-7.0M-179.0M56.0M432.0M-
Total Operating Expenses i27.5B21.1B22.5B20.8B19.1B
Operating Income i11.9B12.8B18.1B17.9B11.4B
Operating Margin % i21.1%23.5%31.2%31.9%24.8%
Non-Operating Items
Interest Income i648.0M540.0M186.0M39.0M174.0M
Interest Expense i2.8B2.2B2.2B2.4B2.5B
Other Non-Operating Income-6.0B-4.8B-2.6B-2.6B-5.7B
Pre-tax Income i3.7B6.2B13.5B13.0B3.4B
Income Tax i-570.0M1.4B1.6B1.4B-1.2B
Effective Tax Rate % i-15.3%22.0%12.1%11.1%-36.0%
Net Income i4.3B4.9B11.8B11.5B4.6B
Net Margin % i7.6%9.0%20.4%20.6%10.1%
Key Metrics
EBITDA i17.7B17.3B24.3B24.0B12.4B
EPS (Basic) i$2.40$2.73$6.69$6.53$2.62
EPS (Diluted) i$2.39$2.72$6.63$6.45$2.62
Basic Shares Outstanding i17690000001768000000176918129417683376961765132819
Diluted Shares Outstanding i17690000001768000000176918129417683376961765132819

Income Statement Trend

AbbVie Balance Sheet From 2020 to 2024

Metric20242023202220212020
Assets
Current Assets
Cash & Equivalents i5.5B12.8B9.2B9.7B8.4B
Short-term Investments i31.0M2.0M28.0M84.0M30.0M
Accounts Receivable i10.9B11.2B11.3B10.0B8.8B
Inventory i4.2B4.1B3.6B3.1B3.3B
Other Current Assets4.9B4.9B4.4B5.0B-
Total Current Assets i25.6B33.0B28.5B27.9B24.2B
Non-Current Assets
Property, Plant & Equipment i00000
Goodwill i130.0B120.2B131.8B140.7B149.1B
Intangible Assets i60.1B55.6B67.4B76.0B82.9B
Long-term Investments-----
Other Non-Current Assets9.1B8.5B5.6B4.9B4.9B
Total Non-Current Assets i109.6B101.7B110.3B118.6B126.4B
Total Assets i135.2B134.7B138.8B146.5B150.6B
Liabilities
Current Liabilities
Accounts Payable i2.9B3.7B2.9B2.9B2.3B
Short-term Debt i6.8B7.2B4.1B12.5B8.5B
Current Portion of Long-term Debt-----
Other Current Liabilities-----
Total Current Liabilities i38.7B37.8B29.5B35.2B28.7B
Non-Current Liabilities
Long-term Debt i60.3B52.2B59.1B64.2B77.6B
Deferred Tax Liabilities i2.6B2.0B2.2B3.0B3.6B
Other Non-Current Liabilities27.6B28.6B26.0B22.1B20.3B
Total Non-Current Liabilities i93.0B86.5B92.0B95.9B108.8B
Total Liabilities i131.8B124.3B121.5B131.1B137.5B
Equity
Common Stock i18.0M18.0M18.0M18.0M18.0M
Retained Earnings i-7.9B-1.0B4.8B3.1B1.1B
Treasury Stock i8.2B6.5B4.6B3.1B2.3B
Other Equity-----
Total Shareholders Equity i3.4B10.4B17.3B15.4B13.1B
Key Metrics
Total Debt i67.1B59.4B63.3B76.7B86.1B
Working Capital i-13.2B-4.8B-1.1B-7.3B-4.5B

Balance Sheet Composition

AbbVie Cash Flow Statement From 2020 to 2024

Metric20242023202220212020
Operating Activities
Net Income i4.3B4.9B11.8B11.5B4.6B
Depreciation & Amortization i8.4B8.7B8.5B8.5B6.5B
Stock-Based Compensation i911.0M747.0M671.0M692.0M753.0M
Working Capital Changes i-3.1B3.0B170.0M-1.0B-28.0M
Operating Cash Flow i13.5B19.2B22.4B22.8B17.5B
Investing Activities
Capital Expenditures i-974.0M-777.0M-695.0M-787.0M-798.0M
Acquisitions i-20.5B-1.2B-794.0M-1.9B-39.6B
Investment Purchases i-73.0M-77.0M-1.4B-119.0M-61.0M
Investment Sales i555.0M55.0M1.5B98.0M1.5B
Investing Cash Flow i-20.8B-2.0B-623.0M-2.3B-37.6B
Financing Activities
Share Repurchases i-1.7B-2.0B-1.5B-934.0M-978.0M
Dividends Paid i-11.0B-10.5B-10.0B-9.3B-7.7B
Debt Issuance i17.0B02.0B1.0B3.0B
Debt Repayment i-14.6B-4.1B-14.4B-9.4B-5.7B
Financing Cash Flow i-10.4B-17.4B-25.1B-19.3B-11.7B
Free Cash Flow i17.8B22.1B24.2B22.0B16.8B
Net Change in Cash i-17.8B-170.0M-3.3B1.2B-31.8B

Cash Flow Trend

AbbVie Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) 97.94
Forward P/E 17.04
Price to Book -2,641.62
Price to Sales 6.26
PEG Ratio -3.02

Profitability Ratios

Profit Margin 6.45%
Operating Margin 37.52%
Return on Equity 112.85%
Return on Assets 8.87%

Financial Health

Current Ratio 0.74
Debt to Equity -511.49
Beta 0.50

Per Share Data

EPS (TTM) $2.11
Book Value per Share $-0.10
Revenue per Share $32.98

Peer Financial Comparison

CompanyMarket CapP/E RatioP/B RatioROEProfit MarginDebt/Equity
abbv365.1B97.94-2,641.62112.85%6.45%-511.49
Eli Lilly and 618.5B45.0033.8686.29%25.91%217.89
Johnson & Johnson 428.2B19.065.4530.21%25.00%64.69
Merck & Co 212.1B13.094.3435.42%25.79%72.16
Amgen 159.6B24.2221.4899.14%18.96%756.65
Gilead Sciences 146.4B23.417.4533.40%21.87%127.34

Financial data is updated regularly. All figures are in the company's reporting currency.